IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO

Preferred name

Main Affiliation

Facultad de Medicina Clínica Alemana Universidad del Desarrollo

s.ibanez@udd.cl

ORCID

0000-0002-9577-3078

Scopus Author ID

57211180704, 35086157600

Now showing 1 - 10 of 19

Some of the metrics are blocked by your
consent settings
Características clínicas, tratamientos y su impacto en la calidad de vida y productividad laboral en pacientes chilenos con espondiloartritis: Un estudio basado en encuestas web
(Sociedad Chilena de Reumatologia, 2025-07-14)
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
Díaz Álvarez, Pamela
;
Zúniga Cruz, Leana
Some of the metrics are blocked by your
consent settings
AB0658 TWO-YEAR PERSISTENCE OF FIRST-LINE BIOLOGICAL OR JAK INHIBITOR TREATMENT IN PATIENTS WITH LONG-STANDING RHEUMATOID ARTHRITIS AND FAILURE TO TRIPLE THERAPY WITH SYNTHETIC DMARDs
(Elsevier BV, 2024-06)
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
D. García
;
M.P. Poblete
;
F. Valenzuela
;
M. Canals
2
Some of the metrics are blocked by your
consent settings
Non-Infectious Uveitis and Pregnancy, is There an Optimal Treatment? Uveitis Course and Safety of Uveitis Treatment in Pregnancy
(2024)
Magdalene Yin Lin Ting
;
Fabian Vega-Tapia
;
Rodrigo Anguita
;
Loreto Cuitino
;
Rodrigo A. Valenzuela
7Scopus© Citations 7
Some of the metrics are blocked by your
consent settings
A case report of sarcoidosis and ulcerative colitis: overlap or coexistence
(Sociedad Espanola de Patologia Digestiva (SEPD), 2025)
Alex Fabián Arenas Aravena
;
Diego Ruedi
;
Matías Sanhueza
;
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
Gonzalo Carrasco-Avino
4Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
CHILEAN AXIAL SPONDYLOARTHRITIS PATIENTSREPORT HIGH DISEASE BURDEN AND IMPAIRED WORK ACTIVITY – AN INTERNET SURVEY IN 472 PATIENTS
(2019)
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
Rianne van Bentum
;
VALENZUELA LETELIER, OMAR ANTONIO
;
Irene van der Horst-Bruinsma
3
Some of the metrics are blocked by your
consent settings
OP0047 IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PERSPA STUDY
(2021)
C. López-Medina
;
S. Chevret
;
A. Moltó
;
J. Sieper
;
M. T. Duruöz
<jats:sec><jats:title>Background:</jats:title><jats:p>Patients with a diagnosis of Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) may have predominant axial or peripheral symptoms, and the frequency and distribution of these symptoms may determine the clinical diagnosis by the rheumatologist (“clinical clusters”). Clustering analysis represents an unsupervised exploratory analysis which tries to identify homogeneous groups of cases (“statistical clusters”) without prior information about the membership for any of the cases.</jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p>To identify “statistical clusters” of peripheral involvement according to the specific location of these symptoms in the whole spectrum of SpA and PsA (without prior information about the diagnosis of the patients), and to evaluate whether these “statistical clusters” are in agreement with the “clinical clusters”.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Cross-sectional and multicentre study with 24 participating countries. Consecutive patients considered by their treating rheumatologist as suffering from either PsA, axial SpA (axSpA) or peripheral SpA (pSpA) were enrolled. Four different cluster analyses were conducted: the first one using information about the specific location from all the peripheral musculoskeletal manifestations (i.e., peripheral arthritis, enthesitis and dactylitis), and thereafter a cluster analysis for each peripheral manifestation individually. Multiple correspondence analyses and k-means clustering methods were used. Distribution of peripheral manifestations and clinical characteristics were compared across the different clusters.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>4465 patients were included in the analysis. Two clusters were found with regard to the <jats:italic>location of all the peripheral manifestations</jats:italic> (Fig. 1). Cluster 1 showed a low prevalence of peripheral manifestations in comparison with cluster 2; however, when peripheral involvement appeared in cluster 1, this was mostly represented by arthritis of hip, knee and ankle, as well as enthesitis of the heel. Patients from cluster 1 showed a higher prevalence of males (63% vs 44%), HLA-B27 positivity (69% vs 38%) and axial involvement (80% vs 52%), as well as more frequent diagnosis of axSpA (66% vs 21%) and more frequently fulfilling the ASAS axSpA criteria (69% vs. 41%). Patients from cluster 2 showed a higher prevalence of psoriasis (63% vs 25%), a more frequent diagnosis of PsA (61% vs 19%), and they fulfilled more frequently the peripheral ASAS (26% vs 11%) and the CASPAR criteria (57% vs 19%).</jats:p><jats:fig id="F1" position="float" orientation="portrait"><jats:label>Figure 1.</jats:label><jats:caption><jats:p>Distribution of the peripheral involvement across clusters</jats:p></jats:caption><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EUROAB-2021-OP-2-OP0047_F0001" position="float" orientation="portrait" /></jats:fig><jats:p>Three clusters were found with regard to the <jats:italic>location of the peripheral arthritis.</jats:italic> Clusters 2 and 3 showed a high prevalence of peripheral joint disease, although this was located more predominantly in the lower limbs in cluster 2, and in the upper limbs in cluster 3. Cluster 1 showed a higher prevalence of males, HLA-B27 positivity, axial involvement, a lower presence of psoriasis, a more frequent diagnosis of axSpA and fulfilling the ASAS axSpA criteria in comparison with clusters 2 and 3, respectively. Clusters 2 and 3 showed a higher prevalence of enthesitis and dactylitis in comparison with cluster 1, a more frequent diagnosis of PsA and fulfillment of the CASPAR criteria.</jats:p><jats:p>Information about the <jats:italic>location of enthesitis</jats:italic> exhibited three groups: cluster 1 showed a very low prevalence of enthesitis, while cluster 2 and 3 showed a high prevalence of enthesitis, with a predominant involvement of axial enthesis in cluster 2 and peripheral enthesitis in cluster 3.</jats:p><jats:p>Finally, the <jats:italic>analysis of dactylitis</jats:italic> also exhibited three clusters that showed a very low prevalence of dactylitis, predominantly toes and predominantly fingers involvement, respectively.</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>These results suggest the presence of heterogeneous patterns of peripheral involvement in SpA and PsA patients without clearly defined groups, confirming the clear overlap of these peripheral manifestations across the different underlying diagnoses.</jats:p></jats:sec><jats:sec><jats:title>Acknowledgements:</jats:title><jats:p>This study was conducted under the umbrella of ASAS with unrestricted grant of Abbvie, Pfizer, Lilly, Novartis, UCB, Janssen and Merck.</jats:p></jats:sec><jats:sec><jats:title>Disclosure of Interests:</jats:title><jats:p>None declared</jats:p></jats:sec>
4
Some of the metrics are blocked by your
consent settings
Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study
(2020)
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
8
Some of the metrics are blocked by your
consent settings
Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability - a Web Survey in 472 Patients
(2019)
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
VALENZUELA LETELIER, OMAR ANTONIO
;
Rianne Van Bentum
;
Irene Van Der Horst-bruinsma
5
Some of the metrics are blocked by your
consent settings
The Persistence of Biologic Therapies for Psoriatic Arthritis
(2024)
Magdalena Jasmen
;
Dominga García
;
IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO
;
Pamela Díaz
<jats:title>Abstract</jats:title> <jats:p>Drug persistence is a crucial measure of long-term efficacy, safety, and patient satisfaction. Lack of persistence can increase healthcare costs and morbidity and mortality rates. This review aimed to consolidate available data on drug persistence for various biological treatments used as the primary intervention for psoriatic arthritis and identify factors associated with nonpersistence. Reports indicate variable 1-year persistence rates for biologic therapies, ranging from 37% to 73%. Specifically, tumor necrosis factor inhibitors have shown fluctuating 1-year persistence rates ranging from 32% to 85%. IL-12/23 and IL-23 inhibitors demonstrate persistence rates of 25% to 89%, whereas data for IL-17 and JAK inhibitors are more limited, ranging from 51% to 77%. Factors such as female sex and a higher burden of comorbidities have been associated with an increased risk of nonpersistence, although evidence regarding other factors remains scarce. The significant variability in reported persistence rates may be attributed to differences in treatment gaps and methodologies across studies. Addressing and mitigating the factors leading to nonpersistence is essential for improving treatment outcomes in psoriatic arthritis.</jats:p>
Scopus© Citations 1 1
Some of the metrics are blocked by your
consent settings
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia
(2020)
VALENZUELA LETELIER, OMAR ANTONIO
;
IBAÑEZ, SEBASTIAN
;
M. Cecilia Poli
;
ROESSLER VERGARA, PATRICIA ANDREA
;
AYLWIN RAMIREZ, MABEL CRISTINA
12 1Scopus© Citations 5

IBAÑEZ VODNIZZA, SEBASTIAN EDUARDO

Filters

Settings

Sort By

Results per page